Associated Genetic Biomarkers
NCI Definition: A tumor composed of two or more glial cell types (astrocytes, ependymal cells, and oligodendrocytes). 
Mixed gliomas most frequently harbor alterations in IDH1, TP53, ATRX, TERT, and NOTCH1 .
IDH1 Mutation, IDH1 Codon 132 Missense, IDH1 R132H, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in mixed glioma .
There is 1 clinical trial for mixed glioma, of which 1 is open and 0 are completed or closed. Of the trial that contains mixed glioma as an inclusion criterion, 1 is phase 3 (1 open).
IDH1, IDH2, and del(1)(p10) are the most frequent gene inclusion criteria for mixed glioma clinical trials .
Lomustine, procarbazine, and temozolomide are the most common interventions in mixed glioma clinical trials.
Significant Genes in Mixed Glioma
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.